FOSTER CITY, Calif. & HAYWARD, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced an amendment to their collaboration agreement and a separate equity investment by Gilead of $320 million in Arcus common stock at $21.00 per share. The equity investment and collaboration amendment enable accelerated growth of the companies’ joint development programs that span multiple indications. Additionally, Johanna Mercier, Chief Commercial Officer at Gi ...

The latest trading session saw Gilead Sciences (GILD) ending at $79.48, denoting a +1.34% adjustment from its last day's close. The stock's performance was ahead of the S&P 500's daily gain of 0.29%. At the same time, the Dow lost 0.25%, and the tech-heavy Nasdaq gained 0.43%.The HIV and hepatitis C drugmaker's shares have seen a decrease of 1.54% over the last month, not keeping up with the Medical sector's gain of 2.29% and the S&P 500's gain of 2.08%.The investment community will be paying close attentio ...

Shares of Gilead Sciences, Inc. (GILD) were down 10.15% after it announced that the late-stage study evaluating oncology drug Trodelvy (sacituzumab govitecan) in previously treated metastatic non-small cell lung cancer (“NSCLC”) failed.The phase III study, EVOKE-01, evaluated Trodelvy vis-à-vis docetaxel in patients with metastatic or advanced NSCLC that had progressed on or after platinum-based chemotherapy and checkpoint inhibitor therapy. The study enrolled 603 participants who were randomized equally in ...

Pharmaceutical sector mainstay Gilead Sciences (GILD -10.15%) has had many good days on the stock exchange, but Monday wasn't one of them. On the back of dispiriting clinical trial results for one of its investigational medications, investors sent the company's share price down by more than 10%. And that was on a day when the bellwether S&P 500 index ended in positive territory, rising almost 0.3%.Trodelvy didn't meet its latest primary endpointThat trial was a late-stage one for Trodelvy, an approved cance ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

Shares of Gilead fell more than 9% on Monday after a key drug from the company did not significantly extend the lives of patients with a certain lung cancer in a late-stage trial.The results are a blow to Gilead, which is working to become a power player in the cancer space. The treatment, Trodelvy, is one of Gilead's best-selling cancer drugs, contributing roughly a third of its $769 million in oncology sales during the third quarter.The phase-three study is part of an effort to expand the use of Trodelvy, ...

Gilead Sciences Inc (NASDAQ: GILD) says its drug conjugate Trodelvy disappointed in a late-stage cancer trial. Shares of the biotech firm opened about 10% down today.Trodelvy failed to meet primary endpointCopy link to sectionTrodelvy did not meet the “primary endpoint of overall survival in previously treated metastatic non-small cell lung cancer”. EVOKE-01 – the aforementioned phase three trial evaluated the drug conjugate versus docetaxel, as per a press release on Monday.The news arrives only days befor ...

Shares of Gilead Sciences Inc. GILD, +1.03% tumbled 10.9% beating in premarket trading Monday, to pullback from an 11-month high, after the biotechnology company disappointing trial results of its lung cancer treatment. That selloff would put the stock in danger of the biggest one-day decline since it plunged 14.3% on Dec. 22, 2014. The company said the Phase 3 Evoke-01 study of Trodelvy vs. docetaxel did not meet its primary endpoint of overall survival in previously treated metastatic non-small cell lung ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Phase 3 EVOKE-01 study did not meet its primary endpoint of overall survival (OS) in previously treated metastatic non-small cell lung cancer (NSCLC). EVOKE-01 is evaluating Trodelvy® (sacituzumab govitecan-hziy; SG) vs. docetaxel in patients with metastatic or advanced NSCLC that had progressed on or after platinum-based chemotherapy and checkpoint inhibitor therapy. A numerical improvement in OS favoring S ...

Gilead Sciences (GILD) closed at $86.48 in the latest trading session, marking a +0.57% move from the prior day. The stock outpaced the S&P 500's daily loss of 0.56%. Elsewhere, the Dow saw a downswing of 0.25%, while the tech-heavy Nasdaq depreciated by 0.59%.Shares of the HIV and hepatitis C drugmaker witnessed a gain of 8.18% over the previous month, beating the performance of the Medical sector with its gain of 3.8% and the S&P 500's gain of 1.2%.Analysts and investors alike will be keeping a close eye ...